<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004485</url>
  </required_header>
  <id_info>
    <org_study_id>199/14243</org_study_id>
    <secondary_id>FHCRC-1373.00</secondary_id>
    <nct_id>NCT00004485</nct_id>
  </id_info>
  <brief_title>Bone Marrow Transplantation in Treating Children With Sickle Cell Disease</brief_title>
  <official_title>Phase I/II Study of Induction of Stable Mixed Chimerism After Bone Marrow Transplantation From HLA-Identical Donors in Children With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Sickle cell disease is an inherited disorder in which abnormal, crescent-shaped&#xD;
      red blood cells interfere with the ability of the blood to carry oxygen through the body and&#xD;
      can cause severe pain, stroke, and organ damage. Bone marrow transplantation, is a procedure&#xD;
      in which the soft, sponge-like tissue in the center of bones producing white blood cells, red&#xD;
      blood cells, and platelets is replaced by bone marrow from a another person. Bone marrow&#xD;
      transplantation may be an effective treatment in relieving the symptoms of sickle cell&#xD;
      disease.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of bone marrow transplantation in&#xD;
      treating children who have sickle cell disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a multicenter study. Patients undergo total body irradiation on day&#xD;
      0, followed by allogeneic bone marrow transfusion. Patients also receive fludarabine IV daily&#xD;
      and cyclosporine IV twice a day on days -1 to 1. Patients then receive oral cyclosporine on&#xD;
      days 1-90, and oral mycophenolate mofetil twice a day on days 0-27.&#xD;
&#xD;
      Patients are followed for 100 days, monthly for 6 months and then annually for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>50</enrollment>
  <condition>Sickle Cell Anemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Marrow Transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Diagnosis of sickle cell anemia with clinically severe disease manifestations defined by:&#xD;
        Recurrent painful events (at least 2 painful events in past year) which cannot be explained&#xD;
        by other causes Pain lasts at least 4 hours Requires treatment with parenteral narcotics,&#xD;
        equianalgesic dose of oral narcotics, or parenteral nonsteroidal antiinflammatory drugs&#xD;
        Acute chest syndrome (ACS) with at least 2 episodes within past 2 years that required&#xD;
        hospitalization, oxygen, and RBC transfusion Any combination of painful events and ACS&#xD;
        episodes that total 2 events within the past year Abnormal cerebral MRI, abnormal&#xD;
        angiography (MR or conventional), and abnormal neuropsychologic testing performance&#xD;
&#xD;
        No stage III or IV sickle cell lung disease&#xD;
&#xD;
        Genotypically HLA identical sibling donor available&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
        No prior transfusions with greater than 5 units RBC&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Performance status: Karnofsky 70-100%&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No active hepatitis&#xD;
&#xD;
          -  No moderate/severe portal fibrosis&#xD;
&#xD;
        Renal: Glomerular filtration rate at least 30% predicted for age&#xD;
&#xD;
        Neurologic:&#xD;
&#xD;
          -  No severe residual functional neurologic impairment&#xD;
&#xD;
          -  Hemiplegia alone allowed&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Walters</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital of Oakland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>September 8, 2008</last_update_submitted>
  <last_update_submitted_qc>September 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2008</last_update_posted>
  <keyword>genetic diseases and dysmorphic syndromes</keyword>
  <keyword>hematologic disorders</keyword>
  <keyword>rare disease</keyword>
  <keyword>sickle cell anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

